Editors
Paolo A. Ascierto, MD, PhD
Istituto Nazionale Tumori IRCCS ‘Fondazione G. Pascale’, Naples, Italy
Professor Paolo A. Ascierto obtained his medical degree from the University of Naples, Italy, where he subsequently earned his Board Certification in Oncology. He went on to serve consecutive positions at the National Tumour Institute ‘Fondazione G. Pascale’ in Naples, as a postdoctoral fellow and then as Vice Director of the Department of Clinical Immunology. Professor Ascierto is currently Director of the Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics at that same institution. He is Associate Editor for Onco-Immunology of Annals of Oncology, Associate Editor of the Journal for ImmunoTherapy of Cancer, Chief Section Editor for the Combination Strategies section of the Journal of Translational Medicine and a member of the Editorial Board for ESMO Open.
He has been a valued invited speaker at more than 450 national and international meetings and is an active member of several cancer societies. Professor Ascierto has presided as Principal Investigator on over 150 clinical trials and authored more than 500 publications in peer-reviewed journals. His interests are skin cancer molecular biology, molecular markers for tumour progression, targeted therapies, vaccination treatments and immunotherapy, and combination treatment approaches.
Iwona Lugowska, MD, PhD
Maria Skłodowska-Curie National Research Institute of Oncology (MSCI), Warsaw, Poland
Professor Iwona Lugowska is Plenipotentiary Director for International Affairs, Head of the Early Phase Clinical Trials Unit, Leader of the Centre of Excellence for Precision Oncology, Coordinator of the Centre for Research and Development and Consultant in Oncology in the Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Skłodowska-Curie National Research Institute of Oncology (MSCI), Warsaw, Poland.
Professor Lugowska is Chair of the European Society for Medical Oncology (ESMO) Educational Publications Working Group, a board member of the European Organisation for Research and Treatment of Cancer (EORTC), a Horizon Europe, Mission: Cancer representative for Poland and a member of the Ethics Committee at MSCI. She received an award from the American Society of Clinical Oncology (ASCO) IDEA Program 2010, visited the Memorial Sloan Kettering Cancer Center, New York (mentor, Robert Maki), and undertook a fellowship at the Sir Bobby Robson Cancer Trials Research Centre, Newcastle, UK (mentor, Ruth Plummer).
Her main fields of interest are sarcoma, melanoma research, immunotherapy, precision oncology and early phase clinical trials. She also developed a Clinical Support System for the management of gastrointestinal stromal tumours (GISTs).
Ruth Plummer, MD, PhD
Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust; Newcastle University, Newcastle upon Tyne, UK
Ruth Plummer
Ruth Plummer is Professor of Experimental Cancer Medicine, Newcastle University and an honorary consultant medical oncologist in Newcastle Hospitals NHS Foundation Trust, UK. She directs the Sir Bobby Robson Cancer Trials Research Centre and leads the Newcastle Experimental Cancer Medicine Centre and Cancer Research UK (CRUK) Newcastle Cancer Centre. She has taken multiple agents targeting DNA damage response (DDR) into the clinic, including the first-in-human PARP and ATR inhibitors. In addition, she has an active clinical practice treating skin cancer, in both the advanced and adjuvant settings, and with an associated clinical trials portfolio including both early and later phase trials.
Nationally she sits on grant funding committees for CRUK, the Medical Research Council (MRC) and the National Institute for Health Research (NIHR) and was elected a Fellow of the Academy of Medical Sciences in 2018 for her work developing PARP inhibitors as novel cancer treatments for patients.
Contributors
PA Ascierto
Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS ‘Fondazione G. Pascale’, Naples, Italy
M Battistella
Pathology, AP-HP, Saint-Louis Hospital, Paris, France
R Dummer
Faculty of Medicine, University of Zurich, Zurich, Switzerland
AMM Eggermont
Department of Surgical Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
F Herms
Dermatology, AP-HP, Saint-Louis Hospital, Paris, France
AM Grimaldi
Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS ‘Fondazione G. Pascale’, Naples, Italy
K Homicsko
Department of Oncology CHUV, Lausanne, Switzerland
C Kelly
Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust; Newcastle University, Newcastle upon Tyne, UK
C Lebbé
Université de Paris, INSERM U976, Paris, France
I Lugowska
Early Phase Clinical Trials Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
D Massi
Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
G McArthur
Peter MacCallum Cancer Centre, Victoria, Australia
O Michielin
Department of Oncology, CHUV, Lausanne, Switzerland
P Nathan
Mount Vernon Cancer Centre, Northwood, UK
G Palmieri
Unit of Cancer Genetics, Institute of Genetic and Biomedical Research (IRGB), National Research Council (CNR), Sassari, Italy
R Plummer
Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust; Newcastle University, Newcastle upon Tyne, UK
E Ramelyte
Department of Dermatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
P Rutkowski
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
JJ Sacco
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool; The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK
D Schadendorf
Department of Dermatology, University Hospital Essen, Essen, Germany
M Slowinska
Dermatological Clinic, Military Institute of Medicine, Central Clinical Hospital of the Ministry of Defence in Warsaw, Warsaw, Poland
ACJ van Akkooi
Department of Surgical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, Netherlands
A Zaremba
Department of Dermatology, University Hospital Essen, Essen, Germany
M Zdzienicki
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
